The therapeutic success of anti-SIRPα blocking Abs in tumors SIRPα-positives, might be based on the activation of the ADCP mechanism against tumor cells by macrophages together with the elimination of the phagocytosis blockade exerted by the CD47-SIRPα interaction. The gene discussed is SIRPA; the disease is neoplasm.